ABBV-142
Phase 2Small molecule
AbbVieABBV-142 is one of 43 small molecule programs targeting Adverse Events. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Idiopathic Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Esbriet
LLegacy Health System
Approved
Medrol
PfizerApproved
Viagra
VViatris Specialty LLC
Approved
Remodulin
United TherapeuticsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Qvar
SSchering-Plough
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adverse Events1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABBV-142. EMBL-EBI & Wellcome Sanger Institute.
- [4]